TNDM vs. IART, NARI, ICUI, ATEC, PRCT, LMAT, NVCR, AXNX, ATRC, and MDXG
Should you be buying Tandem Diabetes Care stock or one of its competitors? The main competitors of Tandem Diabetes Care include Integra LifeSciences (IART), Inari Medical (NARI), ICU Medical (ICUI), Alphatec (ATEC), PROCEPT BioRobotics (PRCT), LeMaitre Vascular (LMAT), NovoCure (NVCR), Axonics (AXNX), AtriCure (ATRC), and MiMedx Group (MDXG). These companies are all part of the "surgical & medical instruments" industry.
Integra LifeSciences (NASDAQ:IART) and Tandem Diabetes Care (NASDAQ:TNDM) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, community ranking, profitability and media sentiment.
In the previous week, Tandem Diabetes Care had 7 more articles in the media than Integra LifeSciences. MarketBeat recorded 15 mentions for Tandem Diabetes Care and 8 mentions for Integra LifeSciences. Integra LifeSciences' average media sentiment score of 1.30 beat Tandem Diabetes Care's score of 0.26 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.
84.8% of Integra LifeSciences shares are owned by institutional investors. 3.1% of Integra LifeSciences shares are owned by insiders. Comparatively, 2.5% of Tandem Diabetes Care shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Integra LifeSciences has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.
Integra LifeSciences has a net margin of 4.39% compared to Integra LifeSciences' net margin of -29.77%. Tandem Diabetes Care's return on equity of 15.19% beat Integra LifeSciences' return on equity.
Tandem Diabetes Care received 130 more outperform votes than Integra LifeSciences when rated by MarketBeat users. Likewise, 60.95% of users gave Tandem Diabetes Care an outperform vote while only 58.39% of users gave Integra LifeSciences an outperform vote.
Integra LifeSciences currently has a consensus target price of $44.89, indicating a potential upside of 58.39%. Tandem Diabetes Care has a consensus target price of $39.45, indicating a potential upside of 11.96%. Given Tandem Diabetes Care's higher possible upside, equities analysts clearly believe Integra LifeSciences is more favorable than Tandem Diabetes Care.
Integra LifeSciences has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.
Summary
Integra LifeSciences beats Tandem Diabetes Care on 10 of the 17 factors compared between the two stocks.
Get Tandem Diabetes Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tandem Diabetes Care Competitors List
Related Companies and Tools
